Lymphoid Neoplasm

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 15339850 · Rasmussen et al., 2005 · Open in CIViC

In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC)

PMID 11050000 · Rowley et al., 2000 · Open in CIViC

In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC)

PMID 16497971 · Hoang et al., 2006 · Open in CIViC

In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC)

PMID 12483530 · Rowley et al., 2002 · Open in CIViC

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including KRAS.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

This retrospective study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR … (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions who were treated with a combination of tyrosine kinase … (full text at CIViC)

PMID 31434701 · Tanasi et al., 2019 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations.

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations. The rate of mut… (full text at CIViC)

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

In this preclinical study, the sensitivity of Multiple Myeloma tumors harboring 1q21 amplification to MCL-1 inhibitor S63845 was tested. The effect of the MCL-1 inhibitor was tested in 21 human myelom… (full text at CIViC)

PMID 31856269 · Slomp et al., 2019 · Open in CIViC

Multiple studies have demonstrated an enrichment for somatic missense mutations in MEF2B including multiple hot spots.

PMID 21796119 · Morin et al., 2011 · Open in CIViC

[the study] identified 25 significantly mutated genes, including known drivers such as ataxia-telangectasia mutated (ATM), cyclin D1 (CCND1), and the tumor suppressor TP53; mutated genes encoding the … (full text at CIViC)

PMID 24145436 · Beà et al., 2013 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations.

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

This study was an international, multi-center retrospective analysis of 107 patients with MEF2D rearrangements, with information collected from 14 different regional study groups. The aim was to asses… (full text at CIViC)

PMID 36309560 · Ohki et al., 2023 · Open in CIViC

This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC)

PMID 31434701 · Tanasi et al., 2019 · Open in CIViC

In this study, 560 cases of B-ALL were analyzed by RNAseq, 22 (3.9%) of which (3.9%) demonstrated rearrangements of MEF2D at chromosome 1q21–22, encoding myocyte enhancer factor 2D, representing 15 of… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

MEF2D encodes myocyte enhancer factor 2D and is mapped to chromosome 1q21–22. It is expressed throughout B-cell differentiation and inactivation of Mef2c/d results in an arrest in B-lymphoid maturatio… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC)

PMID 23292937 · Zhang et al., 2013 · Open in CIViC

The authors performed an integrative analysis of genomes, exomes and transcriptome data from DLBCL and identified recurrent coding and non-coding loci that are commonly mutated in DLBCL

PMID 30275490 · Arthur et al., 2018 · Open in CIViC

A targeted sequencing study of 135 relapsed/refractory DLBCL patients identified an association between missense mutations in MS4A1 and acquired resistance to R-CHOP.

PMID 32589730 · Rushton et al., 2020 · Open in CIViC

In this 2014 genomic profiling study of 1,725 patients with precursor B-cell acute lymphoblastic leukemia (B-ALL), the authors define the high-risk "Philadelphia chromosome-like" (Ph-like or BCR::ABL1… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strong… (full text at CIViC)

PMID 27276402 · Suzuki et al., 2016 · Open in CIViC

BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic mal… (full text at CIViC)

PMID 21889194 · Delmore et al., 2011 · Open in CIViC

MYC translocations, often (but not always) involving immunoglobulin loci, are common in DLBCL and one of two defining features of high-grade B-cell lymphoma with MYC and BCL2 rearrangements

PMID 35653592 · Campo et al., 2022 · Open in CIViC

MYC and BCL2 rearrangements together are defining diagnostic features of this new entity

PMID 35653592 · Campo et al., 2022 · Open in CIViC

In 2016 the WHO added a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with MYC AND [BCL2 OR BCL6] translocations. These represent less than 1… (full text at CIViC)

PMID 28600333 · Friedberg, 2017 · Open in CIViC

A meta-analysis of 40 published studies on 2736 DLBCL patients. The MYD88 L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This … (full text at CIViC)

PMID 28496180 · Lee et al., 2017 · Open in CIViC

A prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with M… (full text at CIViC)

PMID 25853747 · Treon et al., 2015 · Open in CIViC

This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes

PMID 29641966 · Schmitz et al., 2018 · Open in CIViC

Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL including NFKBIE.

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes

PMID 29641966 · Schmitz et al., 2018 · Open in CIViC

The authors performed an integrative analysis of genomes, exomes and transcriptome data from DLBCL and identified recurrent coding and non-coding loci that are commonly mutated in DLBCL

PMID 30275490 · Arthur et al., 2018 · Open in CIViC